Analysis of the 11β-Hydroxysteroid Dehydrogenase Type 2 Gene (HSD11B2) in Human Essential Hypertension

[1]  F. Frey,et al.  Epigenetic regulation of 11β-hydroxysteroid dehydrogenase type 2 expression , 2004 .

[2]  F. Frey,et al.  In vivo footprinting of the human 11beta-hydroxysteroid dehydrogenase type 2 promoter: evidence for cell-specific regulation by Sp1 and Sp3. , 2002, The Journal of biological chemistry.

[3]  A. de la Sierra,et al.  Molecular Basis of Salt Sensitivity in Human Hypertension: Evaluation of Renin-Angiotensin-Aldosterone System Gene Polymorphisms , 2001, Hypertension.

[4]  P. Manunta,et al.  CA-Repeat polymorphism in intron 1 of HSD11B2 : effects on gene expression and salt sensitivity. , 2000, Hypertension.

[5]  F. Frey,et al.  The role of the 11β‐hydroxysteroid dehydrogenase type 2 in human hypertension , 2000, Journal of hypertension.

[6]  F. Frey,et al.  Molecular basis of human salt sensitivity: the role of the 11beta-hydroxysteroid dehydrogenase type 2. , 1999, The Journal of clinical endocrinology and metabolism.

[7]  F. Cambien,et al.  Structural analysis and evaluation of the 11β‐hydroxysteroid dehydrogenase type 2 (11β‐HSD2) gene in human essential hypertension , 1998, Journal of Hypertension.

[8]  M. New,et al.  A genetic defect resulting in mild low-renin hypertension. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[9]  S. Kato,et al.  A new compound heterozygous mutation in the 11 beta-hydroxysteroid dehydrogenase type 2 gene in a case of apparent mineralocorticoid excess. , 1997, The Journal of clinical endocrinology and metabolism.

[10]  C. Shackleton,et al.  Apparent mineralocorticoid excess in a Brazilian kindred: hypertension in the heterozygote state , 1997, Journal of hypertension.

[11]  B. Walker,et al.  Additional value of measurement of urinary cortisone and unconjugated cortisol metabolites in assessing the activity of 11β‐hydroxysteroid dehydrogenase in vivo , 1997, Clinical endocrinology.

[12]  John Quackenbush,et al.  A nucleotide substitution in the promoter of human angiotensinogen is associated with essential hypertension and affects basal transcription in vitro. , 1997, The Journal of clinical investigation.

[13]  T. Mune,et al.  11β-Hydroxysteroid Dehydrogenase and the Syndrome of Apparent Mineralocorticoid Excess , 1997 .

[14]  T. Mune,et al.  Molecular analysis of 11β-hydroxysteroid dehydrogenase and its role in the syndrome of apparent mineralocorticoid excess , 1997, Steroids.

[15]  C. Shackleton,et al.  Urinary free cortisone and the assessment of 11β‐hydroxysteroid dehydrogenase activity in man , 1996, Clinical endocrinology.

[16]  D. Warnock,et al.  Genetic association of 11 beta-hydroxysteroid dehydrogenase type 2 (HSD11B2) flanking microsatellites with essential hypertension in blacks. , 1996, Hypertension.

[17]  P. Stewart.  11β‐Hydroxysteroid dehydrogenase: implications for clinical medicine , 1996 .

[18]  T. Mune,et al.  Gene structure and chromosomal localization of the human HSD11K gene encoding the kidney (type 2) isozyme of 11 beta-hydroxysteroid dehydrogenase. , 1995, Genomics.

[19]  M. New,et al.  A mutation in the HSD11B2 gene in a family with apparent mineralocorticoid excess. , 1995, The Journal of clinical endocrinology and metabolism.

[20]  Z. Krozowski,et al.  Cloning and tissue distribution of the human 1 lβ-hydroxysteroid dehydrogenase type 2 enzyme , 1994, Molecular and Cellular Endocrinology.

[21]  J. Mason,et al.  Human kidney 11 beta-hydroxysteroid dehydrogenase is a high affinity nicotinamide adenine dinucleotide-dependent enzyme and differs from the cloned type I isoform. , 1994, The Journal of clinical endocrinology and metabolism.

[22]  B. Walker,et al.  Deficient inactivation of cortisol by 11β‐hydroxysteroid dehydrogenase in essential hypertension , 1993, Clinical endocrinology.

[23]  B. Walker,et al.  Tissue-specific distribution of the NAD(+)-dependent isoform of 11 beta-hydroxysteroid dehydrogenase. , 1992, Endocrinology.

[24]  P. White,et al.  The human gene for 11 beta-hydroxysteroid dehydrogenase. Structure, tissue distribution, and chromosomal localization. , 1991, The Journal of biological chemistry.

[25]  N. Fineberg,et al.  Responses to Volume Expansion and Contraction in Categorized Hypertensive and Normotensive Man , 1979, Hypertension.

[26]  Michael Q. Zhang,et al.  A mechanism for exon skipping caused by nonsense or missense mutations in BRCA1 and other genes , 2001, Nature Genetics.

[27]  C. Zoccali,et al.  Prediction and consistency of blood pressure salt-sensitivity as assessed by a rapid volume expansion and contraction protocol. Salt-Sensitivity Study Group of the Italian Society of Hypertension. , 2000, Journal of nephrology.

[28]  F. Frey,et al.  Structural analysis of the 11beta-hydroxysteroid dehydrogenase type 2 gene in end-stage renal disease. , 2000, Kidney international.

[29]  E. Lander,et al.  Characterization of single-nucleotide polymorphisms in coding regions of human genes , 1999 .

[30]  P. Stewart.  11 beta-Hydroxysteroid dehydrogenase: implications for clinical medicine. , 1996, Clinical endocrinology.

[31]  F. Mantero,et al.  Pathogenesis of the type 2 variant of the syndrome of apparent mineralocorticoid excess. , 1990, The Journal of clinical endocrinology and metabolism.